NY-ESO-1 hypomethylation was an independent adverse prognostic marker in patients with NSCLC and demethylation of the NY-ESO-1 promoter was associated with re-expression of NY-ESO-1. This evidence concerns the gene CTAG1B and non-small cell lung carcinoma.